Skip to main content

Table 2 Results of an ANOVA of factors obtained at baseline in 98 ESRD patients awaiting kidney transplantation the model describes 65% of the variance in PWV ( P < 0.0001 )

From: High levels of mannose-binding lectin are associated with lower pulse wave velocity in uraemic patients

Parameter Effect on PWV(m/s) 95% confidence intervals P-value
Intercept -0.14 -3.66; 3.38 0.94
Age (years) 0.12 0.08; 0.16 <0.0001
BP >130/80 mmHg 1.76 0.81; 2.72 0.0005
BP < 130/80 mmHg (reference group) 0   
Number of antihypertensives (n) -0.08 -0.45;0.29 0.65
ISI (index) 0.21 0.07; 0.36 0.0043
OGTT120min 0.33 0.09; 0.56 0.0067
Homocystein (umol/L) 0.03 0.01; 0.05 0.01
MBL Genotype A/A 1.23 -1.21; 3.66 0.32
MBL Genotype A/O 0.18 -1.85; 2.21 0.86
MBL Genotype O/O (reference group) 0   
LogMBL -0.88 -1.85; 0.10 0.0764
Female sex 0.31 -0.81; 1.42 0.58
Male sex (reference group) 0   
ESRD (months) -0.01 -0.03; 0.01 0.22
Augmentation Index -0.01 -0.05; 0.03 0.51
CRP (mg/L) -0.04 -0.11; 0.04 0.32
  1. Kruskal-Wallis one way of variance analysis of the effect on pulse wave velocity (PWV) using factors obtained at baseline. BP: blood pressure; ISI: insulin sensitivity index; OGTT: oral glucose tolerance test; MBL: mannose-binding lectin; ESRD: end-stage renal disease; CRP: C-reactive protein.